<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.106151</article-id><article-id pub-id-type="publisher-id">ACM-36157</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200600000_74575132.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肾移植后糖代谢异常患者血糖变化的影响因素
  Influencing Factors of Blood Glucose Changes in Patients with Abnormal Glucose Metabolism after Kidney Transplantation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>董</surname><given-names>芳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>申</surname><given-names>黎艳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院内分泌科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>05</month><year>2020</year></pub-date><volume>10</volume><issue>06</issue><fpage>997</fpage><lpage>1003</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：新发糖尿病是实体器官移植后常见的严重并发症。患有移植后糖尿病(PTDM)的肾移植受者发生心血管事件及其他不良后果的风险有所增加。本实验旨在研究引起肾移植后高血糖患者最终血糖出现不同结局的影响因素，为预防肾移植后糖尿病提供理论支持。方法：收集2013~2018年在青岛大学附属医院接受肾移植手术后出现糖代谢异常的患者178例。根据术后空腹血糖是否恢复正常，分为一过性糖尿病组和移植后糖尿病组。分析肾移植后糖代谢异常患者血糖难以恢复的影响因素。结果：在178名出现移植后糖代谢异常的患者中，血糖恢复正常者共68例，血糖持续不恢复者共110例。单因素分析结果显示，年龄、体重指数、术前空腹血糖、急性排斥反应、多囊肾、糖尿病家族史在移植后糖尿病组均高于一过性糖尿病组(P &lt; 0.05)。多因素Logistic回归分析显示，年龄、术前空腹血糖、急性排斥反应、多囊肾、糖尿病家族史是肾移植后高血糖无法恢复的影响因素。结论：年龄、术前空腹血糖、急性排斥反应、多囊肾、糖尿病家族史是肾移植后糖代谢异常患者血糖无法恢复的影响因素。
    Objective: New diabetes mellitus is a common serious complication after solid organ transplantation. Compared with patients without diabetes, kidney transplant recipients with post-transplant diabetes mellitus (PTDM) had an increased risk of fatal and non-fatal cardiovascular events and other adverse outcomes, including infection, decreased patient survival, graft rejection, and accelerated graft injury. Identifying high-risk patients and taking measures to reduce the development of PTDM may improve the long-term prognosis of patients and grafts. The purpose of this research was to study the influencing factors of different blood glucose outcomes in patients with hyperglycemia after kidney transplantation, so as to provide theoretical support for the prevention of diabetes after kidney transplantation. Methods: A total of 178 patients with abnormal glucose metabolism after kidney transplantation in affiliated hospital of Qingdao university from 2013 to 2018 were collected. According to whether the fasting blood glucose returned to normal after the operation, it was divided into the transient diabetes group and the post-transplantation diabetes group. Univariate analysis was performed first to select meaningful independent variables, and then multivariate Logistic regression analysis was performed to analyze the factors affecting the recovery of blood glucose in patients with abnormal glucose metabolism after kidney transplantation. Results: Among 178 patients with abnormal glucose metabolism after transplantation, 68 patients had their blood glucose restored to normal, and 110 patients did not. The results of univariate analysis showed that age, body mass index, preoperative fasting glucose, acute rejection, polycystic kidney disease, and family history of diabetes were all higher in the post-transplant diabetes group than in the transient diabetes group (P &lt; 0.05). Multivariate Logistic regression analysis showed that age, preoperative fasting blood glucose, acute rejection, polycystic kidney disease, and family history of diabetes were the influencing factors for the failure of hyperglycemia after renal transplantation. Conclusion: Age, preoperative fasting blood glucose, acute rejection, polycystic kidney disease, and family history of diabetes mellitus are the influencing factors for blood glucose recovery in patients with abnormal glucose metabolism after kidney transplantation. 
  
 
</p></abstract><kwd-group><kwd>肾移植，糖代谢异常，影响因素, Kidney Transplantation</kwd><kwd> Abnormal Glucose Metabolism</kwd><kwd> Influencing Factor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>肾移植后糖代谢异常患者血糖变化的影响因素</title><p>董芳<sup>1</sup>，申黎艳<sup>2</sup></p><p><sup>1</sup>青岛大学医学部，山东 青岛</p><p><sup>2</sup>青岛大学附属医院内分泌科，山东 青岛</p><p>收稿日期：2020年5月25日；录用日期：2020年6月11日；发布日期：2020年6月18日</p><disp-formula id="hanspub.36157-formula29"><graphic xlink:href="//html.hanspub.org/file/21-1571354x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：新发糖尿病是实体器官移植后常见的严重并发症。患有移植后糖尿病(PTDM)的肾移植受者发生心血管事件及其他不良后果的风险有所增加。本实验旨在研究引起肾移植后高血糖患者最终血糖出现不同结局的影响因素，为预防肾移植后糖尿病提供理论支持。方法：收集2013~2018年在青岛大学附属医院接受肾移植手术后出现糖代谢异常的患者178例。根据术后空腹血糖是否恢复正常，分为一过性糖尿病组和移植后糖尿病组。分析肾移植后糖代谢异常患者血糖难以恢复的影响因素。结果：在178名出现移植后糖代谢异常的患者中，血糖恢复正常者共68例，血糖持续不恢复者共110例。单因素分析结果显示，年龄、体重指数、术前空腹血糖、急性排斥反应、多囊肾、糖尿病家族史在移植后糖尿病组均高于一过性糖尿病组(P &lt; 0.05)。多因素Logistic回归分析显示，年龄、术前空腹血糖、急性排斥反应、多囊肾、糖尿病家族史是肾移植后高血糖无法恢复的影响因素。结论：年龄、术前空腹血糖、急性排斥反应、多囊肾、糖尿病家族史是肾移植后糖代谢异常患者血糖无法恢复的影响因素。</p><p>关键词 :肾移植，糖代谢异常，影响因素</p><disp-formula id="hanspub.36157-formula30"><graphic xlink:href="//html.hanspub.org/file/21-1571354x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/21-1571354x7_hanspub.png" /> <img src="//html.hanspub.org/file/21-1571354x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>自1954年以来，美国医生约瑟夫&#183;默里成功地完成了第一例纯合子双胞胎之间的肾移植，开创了器官移植的新纪元。1960年，中国完成了第一例人肾移植。20世纪70年代后，肾移植在我国正式开展。随着肾移植的发展，移植后糖尿病已引起人们的重视。移植后糖尿病(PTDM)是肾移植术后常见的并发症。它最早是由斯塔尔茨等人于1964年发现的。有证据表明，移植后糖尿病降低了移植后患者的生活质量和长期生存率，是导致移植失败和死亡的主要因素之一，也是发生心血管疾病的危险因素之一 [<xref ref-type="bibr" rid="hanspub.36157-ref1">1</xref>]。目前已有大量研究对移植后糖尿病的危险因素及机制进行探讨。对于引起PTDM的危险因素一直是研究热点，掌握PTDM的危险因素，即可早期识别PTDM的高危患者，及早进行临床干预，以减少移植后糖尿病的发生。然而临床中发现，肾移植术后部分患者出现糖代谢异常可以恢复，针对肾移植后糖代谢异常患者血糖变化的研究尚不充分，对引起最终血糖恢复与否的影响因素目前暂无相关研究。</p></sec><sec id="s4"><title>2. 方法</title><sec id="s4_1"><title>2.1. 研究对象</title><p>自2013年1月至2018年6月在青岛大学附属医院行肾移植手术的患者共549名，其中符合纳入标准者共178名，其中男性132名，女性46名。所有患者均于我院肾移植科门诊复诊，随访年限≥1.5年。</p><p>纳入标准：年龄大于或等于18岁；首次进行肾移植手术；手术1月后新发糖代谢异常；随访年限≥1.5年。排除标准：术前、术后资料不全；失访或死亡；联合器官移植者；多次器官移植者；移植失败或移植后1.5年内移植肾失功；术前已确诊糖尿病或已有空腹血糖受损。</p><p>本研究方案经本院伦理委员会批准，且所有研究对象均知情同意。</p></sec><sec id="s4_2"><title>2.2. 研究内容</title><sec id="s4_2_1"><title>2.2.1. 资料收集内容</title><p>通过查阅住院病历和门诊病历以及电话随访的方式，对符合纳入标准的178例肾移植患者的一般资料及实验室检查结果进行回顾性研究。主要收集患者姓名、住院号、联系方式、性别、年龄、身高、体重、体重指数(BMI)、收缩压、舒张压、糖尿病(DM)家族史、原发病是否为多囊肾、术前空腹血糖(FBG)、甘油三酯(TG)、总胆固醇(CHOL)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、乙型肝炎病毒(HBV)感染史、丙型肝炎病毒(HCV)感染史、EB病毒感染史、巨细胞病毒(CMV)感染史、手术时间、移植后是否发生急性排斥反应。</p></sec><sec id="s4_2_2"><title>2.2.2. 诊断标准</title><p>移植后糖尿病(PTDM)的诊断标准使用美国糖尿病协会(ADA)的诊断标准 [<xref ref-type="bibr" rid="hanspub.36157-ref2">2</xref>]：即具有糖尿病症状且空腹血糖(FBG) ≥ 7.0 mmol/L，或随机血糖(RPG) ≥ 11.1 mmol/L，或口服75 g葡萄糖耐量试验(OGTT) 2小时血糖≥11.1 mmol/L。FBG在5.6~6.9 mmol/L诊断为空腹血糖受损(IFG)，OGTT 2 h血糖在7.8~11.1 mmol/L诊断为葡萄糖耐量受损(IGT)。一过性PTDM定义为连续1月或1月以上空腹血糖升高并达到PTDM的诊断标准。空腹定义为至少8小时未摄入热量。</p></sec><sec id="s4_2_3"><title>2.2.3. 研究分组</title><p>根据PTDM的诊断标准，将纳入研究的178名肾移植术后出现糖代谢异常的患者分为PTDM组和一过性PTDM组，PTDM组为术后糖代谢异常持续不恢复的患者。一过性PTDM组为肾移植后出现糖代谢异常但最终血糖恢复正常的患者。</p></sec><sec id="s4_2_4"><title>2.2.4. 肾移植术后免疫抑制治疗方案</title><p>所有手术患者均采用三联治疗方案：他克莫司(FK506)+糖皮质激素+吗替麦考酚酯。肾移植受者均于手术前开始口服他克莫司，起始剂量为0.05~0.25 mg/(kg∙d)，每日分两次口服，每12小时给药一次。根据他克莫司血药浓度来调整剂量。糖皮质激素用量：术后当天给予甲强龙750 mg静滴一次，术后第一、二天给予甲强龙每天500 mg静滴，术后第三天开始改为口服甲泼尼龙每天16 mg。若术后发生急性排斥反应，给予静脉滴注糖皮质激素治疗。</p></sec></sec><sec id="s4_3"><title>2.3. 统计学处理</title><p>应用SPSS 22软件进行统计学分析，对所有计量资料进行正态性检验，符合正态性分布的计量资料，采用两独立样本的t检验，数据用均数&#177;标准差(X &#177; SD)表示。不符合正态性分布的计量资料，采用秩和检验，数据用中位数(四分位数)表示。计数资料采用卡方检验，数据用率或构成比表示。影响因素分析采用Logistic回归。P &lt; 0.05有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 肾移植后糖代谢异常的血糖变化</title><p>术后出现糖代谢异常患者为178名，发生率为32.4%，其中血糖最终恢复正常者共68名，发生率为12.4%，血糖持续不恢复者共110名，均发展为糖尿病，糖尿病发生率为20%。</p></sec><sec id="s5_2"><title>3.2. 肾移植后糖代谢异常患者血糖难以恢复的影响因素分析</title><p>PTDM组的年龄、BMI、术前空腹血糖、糖尿病家族史、多囊肾、急性排斥反应发生率均高于一过性PTDM组，具有统计学差异(P &lt; 0.05)。性别、身高、体重、收缩压、舒张压、巨细胞病毒感染史、EB病毒感染史、乙型肝炎病毒感染史、丙型肝炎病毒感染史、甘油三酯、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇在两组间均无统计学差异(P &gt; 0.05)。结果如表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Analysis of the influencing factors of diabetes and transient diabetes after kidney transplantatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >PTDM</th><th align="center" valign="middle" >一过性PTDM</th><th align="center" valign="middle" >t/X<sup>2</sup>/Z</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >性别(男/女，例)</td><td align="center" valign="middle" >80/30</td><td align="center" valign="middle" >52/16</td><td align="center" valign="middle" >0.307</td><td align="center" valign="middle" >0.579</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >44.66 &#177; 10.51</td><td align="center" valign="middle" >40.06 &#177; 9.45</td><td align="center" valign="middle" >2.944</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" >身高(cm)</td><td align="center" valign="middle" >169.18 &#177; 7.31</td><td align="center" valign="middle" >170.40 &#177; 6.82</td><td align="center" valign="middle" >−1.105</td><td align="center" valign="middle" >0.271</td></tr><tr><td align="center" valign="middle" >体重(kg)</td><td align="center" valign="middle" >71.5 (59.5, 80)</td><td align="center" valign="middle" >66.75 (61, 76)</td><td align="center" valign="middle" >−1.216</td><td align="center" valign="middle" >0.224</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >24.07 (22.39, 28.40)</td><td align="center" valign="middle" >23.15 (19.65, 25.80)</td><td align="center" valign="middle" >−2.347</td><td align="center" valign="middle" >0.019</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >147.71 &#177; 18.62</td><td align="center" valign="middle" >142.56 &#177; 17.43</td><td align="center" valign="middle" >1.837</td><td align="center" valign="middle" >0.068</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >92.82 &#177; 13.66</td><td align="center" valign="middle" >90.91 &#177; 9.38</td><td align="center" valign="middle" >1.012</td><td align="center" valign="middle" >0.313</td></tr><tr><td align="center" valign="middle" >DM家族史(%)</td><td align="center" valign="middle" >13.5</td><td align="center" valign="middle" >2.8</td><td align="center" valign="middle" >6.447</td><td align="center" valign="middle" >0.011</td></tr><tr><td align="center" valign="middle" >多囊肾(%)</td><td align="center" valign="middle" >9.0</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >6.225</td><td align="center" valign="middle" >0.013</td></tr><tr><td align="center" valign="middle" >急性排斥反应(%)</td><td align="center" valign="middle" >11.2</td><td align="center" valign="middle" >2.8</td><td align="center" valign="middle" >4.082</td><td align="center" valign="middle" >0.043</td></tr><tr><td align="center" valign="middle" >HBV感染史(%)</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >1.066</td><td align="center" valign="middle" >0.302</td></tr><tr><td align="center" valign="middle" >HCV感染史(%)</td><td align="center" valign="middle" >6.7</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >2.664</td><td align="center" valign="middle" >0.103</td></tr><tr><td align="center" valign="middle" >EB病毒感染史(%)</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >3.4</td><td align="center" valign="middle" >3.311</td><td align="center" valign="middle" >0.069</td></tr><tr><td align="center" valign="middle" >CMV感染史(%)</td><td align="center" valign="middle" >7.9</td><td align="center" valign="middle" >3.4</td><td align="center" valign="middle" >0.642</td><td align="center" valign="middle" >0.423</td></tr><tr><td align="center" valign="middle" >FBG (mmol/L)</td><td align="center" valign="middle" >4.89 (4.36, 5.81)</td><td align="center" valign="middle" >4.56 (4.04, 4.88)</td><td align="center" valign="middle" >−3.659</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >TG (mmol/L)</td><td align="center" valign="middle" >1.50 (0.88, 2.90)</td><td align="center" valign="middle" >1.59 (1.01, 2.25)</td><td align="center" valign="middle" >−0.024</td><td align="center" valign="middle" >0.981</td></tr><tr><td align="center" valign="middle" >CHOL (mmol/L)</td><td align="center" valign="middle" >4.19 &#177; 1.08</td><td align="center" valign="middle" >4.31 &#177; 0.91</td><td align="center" valign="middle" >−0.741</td><td align="center" valign="middle" >0.460</td></tr><tr><td align="center" valign="middle" >HDL-C (mmol/L)</td><td align="center" valign="middle" >1.02 &#177; 0.32</td><td align="center" valign="middle" >1.11 &#177; 0.29</td><td align="center" valign="middle" >−1.941</td><td align="center" valign="middle" >0.054</td></tr><tr><td align="center" valign="middle" >LDL-C (mmol/L)</td><td align="center" valign="middle" >2.47 &#177; 0.75</td><td align="center" valign="middle" >2.56 &#177; 0.75</td><td align="center" valign="middle" >−0.753</td><td align="center" valign="middle" >0.453</td></tr></tbody></table></table-wrap><p>表1. 肾移植后糖尿病和一过性糖尿病影响因素分析</p><p>将年龄、BMI、FBG、糖尿病家族史、多囊肾和急性排斥反应这六个有统计学意义的变量进行多因素Logistic回归分析，结果如表2。分析结果显示：年龄(OR = 1.065，P = 0.001，95% CI 1.025~1.107)、术前空腹血糖(OR = 2.539，P = 0.000，95% CI 1.558~4.138)、糖尿病家族史(OR = 3.331，P = 0.045，95% CI 1.029~10.786)、多囊肾(OR = 6.287，P = 0.028，95% CI 1.219~34.22)、急性排斥反应(OR = 5.007，P = 0.005，95% CI 1.622~15.454)为肾移植后糖代谢异常患者血糖持续不恢复的影响因素(P &lt; 0.05)，BMI与肾移植后高血糖恢复无关(P &gt; 0.05)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Multivariate Logistic regression analysis of hyperglycemia after kidney transplantatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >β</th><th align="center" valign="middle" >SE</th><th align="center" valign="middle" >Wald</th><th align="center" valign="middle" >OR</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >OR (95% CI)</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.063</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >10.346</td><td align="center" valign="middle" >1.065</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >1.025~1.107</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >0.021</td><td align="center" valign="middle" >0.038</td><td align="center" valign="middle" >0.312</td><td align="center" valign="middle" >1.021</td><td align="center" valign="middle" >0.577</td><td align="center" valign="middle" >0.948~1.100</td></tr><tr><td align="center" valign="middle" >DM家族史</td><td align="center" valign="middle" >1.203</td><td align="center" valign="middle" >0.6</td><td align="center" valign="middle" >4.028</td><td align="center" valign="middle" >3.331</td><td align="center" valign="middle" >0.045</td><td align="center" valign="middle" >1.029~10.786</td></tr><tr><td align="center" valign="middle" >多囊肾</td><td align="center" valign="middle" >1.838</td><td align="center" valign="middle" >0.837</td><td align="center" valign="middle" >4.827</td><td align="center" valign="middle" >6.287</td><td align="center" valign="middle" >0.028</td><td align="center" valign="middle" >1.219~32.44</td></tr><tr><td align="center" valign="middle" >急性排斥反应</td><td align="center" valign="middle" >1.611</td><td align="center" valign="middle" >0.575</td><td align="center" valign="middle" >7.847</td><td align="center" valign="middle" >5.007</td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" >1.622~15.454</td></tr><tr><td align="center" valign="middle" >FBG (mmol/L)</td><td align="center" valign="middle" >0.932</td><td align="center" valign="middle" >0.249</td><td align="center" valign="middle" >13.972</td><td align="center" valign="middle" >2.539</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >1.558~4.138</td></tr></tbody></table></table-wrap><p>表2. 肾移植后高血糖无法恢复的多因素Logistic回归分析</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>观察发现，肾移植后出现糖代谢异常的患者一部分血糖可恢复正常，另一部分血糖无法恢复，呈持续糖代谢异常状态，最终发展为移植后糖尿病。大量研究指出，年龄、BMI、术前高血糖状态、遗传因素、急性排斥反应、免疫抑制剂及糖皮质激素的应用是移植后糖尿病的独立危险因素 [<xref ref-type="bibr" rid="hanspub.36157-ref3">3</xref>] - [<xref ref-type="bibr" rid="hanspub.36157-ref8">8</xref>]。本研究证实，年龄、术前空腹血糖、原发病为多囊肾、术后急性排斥反应、糖尿病家族史是肾移植后糖代谢异常患者血糖无法恢复的影响因素。</p><p>国外研究指出，年龄是肾移植后发生糖尿病的危险因素，年龄越大，术后发生移植后糖尿病可能性越高 [<xref ref-type="bibr" rid="hanspub.36157-ref9">9</xref>]。本研究中，PTDM组年龄明显高于一过性PTDM组，差异有统计学意义(P &lt; 0.05)，提示移植年龄大者，术后出现糖代谢异常难以恢复。同时国外研究表明，术前空腹血糖水平越高，移植后发生糖尿病的危险性越大 [<xref ref-type="bibr" rid="hanspub.36157-ref10">10</xref>]。Cosio [<xref ref-type="bibr" rid="hanspub.36157-ref11">11</xref>] 等人的报告显示移植前血糖水平高是PTDM移植1年后的危险因素。Gomes [<xref ref-type="bibr" rid="hanspub.36157-ref12">12</xref>] 等人研究表明移植前较高的FBG水平和移植前IFG的发生是PTDM发生的预测危险因素。随着移植前FBG水平的升高，风险也随之增加，移植前IFG患者中，70%在1年后出现高血糖。本研究结果显示，PTDM组的术前空腹血糖高于一过性PTDM组，表明术前较高空腹血糖状态是移植后糖代谢异常患者血糖难以恢复的影响因素。术前更低的空腹血糖水平，有利于术后出现糖代谢异常患者的血糖恢复正常。因此对于年龄较大且术前空腹血糖较高的患者，可及早通过饮食、运动甚至是降糖药物控制血糖，有利于减少移植后糖尿病的发生。</p><p>有研究表明，高BMI是肾移植后新发糖尿病的危险因素 [<xref ref-type="bibr" rid="hanspub.36157-ref13">13</xref>]。印度的一项研究表明，超重或肥胖可增加移植后糖尿病的发病风险，移植前高甘油三酯和胆固醇同样是PTDM的危险因素 [<xref ref-type="bibr" rid="hanspub.36157-ref14">14</xref>]。然而，本研究通过比较移植后糖尿病组与一过性糖尿病组发现，BMI、术前甘油三酯及总胆固醇在两组间均无统计学差异，与国外研究不符。考虑到本研究样本量较少，资料仅局限于青岛大学附属医院，患者多来自青岛及周边地区，不排除地域等因素的影响，需进一步增大样本量，扩大样本采集范围对该结论进一步验证。</p><p>常染色体显性多囊肾病(ADPKD)是常见的肾移植病因。针对常染色体多囊肾是否为PTDM的危险因素目前仍存在争议。有研究显示，常染色体显性多囊肾病是移植后糖尿病的危险因素，ADPKD患者在肾移植后第一年内发生移植后糖尿病的风险增加了3倍 [<xref ref-type="bibr" rid="hanspub.36157-ref15">15</xref>]。而一项配对设计多中心研究却显示，ADPKD组与非ADPKD组PTDM发生率分别为19%和18.4%，结果表明，ADPKD不会增加PTDM的风险 [<xref ref-type="bibr" rid="hanspub.36157-ref16">16</xref>]。本研究中PTDM组多囊肾患者所占比例明显高于一过性PTDM组(9% vs 1.1%)，两组间差异有统计学意义，结果提示多囊肾病是肾移植后糖代谢异常患者血糖难以恢复的影响因素(OR = 6.287，P = 0.028，95% CI 1.219~34.22)。对于原发病为多囊肾的患者，移植后高血糖较难恢复正常，更易发展为糖尿病。多囊肾作为不可改变的影响因素，可用于筛查PTDM高危人群，对于患有多囊肾的患者，术后应密切监测血糖，及早发现PTDM患者。</p><p>本研究显示，移植术后发生急性排斥反应同样是移植后糖代谢异常难以恢复的影响因素。Marin等对17l例肾移植患者进行研究，发现在48例发生PTDM的患者中有28例发生术后急性排斥反应 [<xref ref-type="bibr" rid="hanspub.36157-ref17">17</xref>]。本研究表明，PTDM组的急性排斥反应发生率(11.2%)明显高于一过性PTDM组(2.8%)。多因素分析指出急性排斥反应是移植后高血糖难以恢复的影响因素(OR = 5.007，P = 0.005，95% CI 1.622~15.454)。本研究结果显示，对于术后出现糖代谢异常的患者，若发生急性排斥反应，高血糖较难恢复正常，更易发展为PTDM。本研究中，出现急性排斥反应的患者应用糖皮质激素治疗，现已证实，糖皮质激素可增加胰岛素抵抗，促进糖异生，从而升高血糖。另外，急性排斥反应本质上是一种应激反应，可引起体内肾上腺素、生长激素等升糖激素的升高，间接影响血糖水平。观察发现，随着糖皮质激素用量逐渐减少，血糖水平可逐渐下降。因此在临床上，出现急性排斥反应时减少激素的用量，在急性排斥反应得到有效控制后，及时减少免疫抑制剂的应用，减有助于少糖尿病的发生。</p><p>本研究指出，糖尿病家族史也是移植后糖代谢异常难以恢复的影响因素。杨进等人的回顾性研究结果也表明，糖尿病家族史是移植后糖尿病的独立危险因素 [<xref ref-type="bibr" rid="hanspub.36157-ref18">18</xref>]。在一项对1410名肾移植受者的多中心横断面研究中发现，糖尿病家族史阳性可使PTDM的发生风险增加50% [<xref ref-type="bibr" rid="hanspub.36157-ref19">19</xref>]。本研究结果也显示，糖尿病家族史在PTDM组与一过性PTDM组两组间差异有统计学意义(P &lt; 0.05)。有糖尿病家族史的术后糖代谢异常患者，术后高血糖较难恢复正常。因此，对于有糖尿病家族史的肾移植者应密切监测血糖，严格控制术前空腹血糖，对于术后高血糖应及早进行血糖干预，给予更精细的免疫治疗方案，减少糖尿病的发生。</p></sec><sec id="s7"><title>5. 结论</title><p>肾移植后出现糖代谢异常的患者，一部分患者血糖可恢复正常，另一部分患者血糖持续呈糖代谢异常状态，年龄、术前空腹血糖、糖尿病家族史、多囊肾、急性排斥反应是肾移植后糖代谢异常患者血糖无法恢复的影响因素。其中术前空腹血糖为可改变因素，其余均为不可改变因素，不可改变因素可用于筛查高危人群，针对可改变的危险因素，应及早进行干预，以减少PTDM的发生。</p></sec><sec id="s8"><title>致谢</title><p>感谢邓玉杰老师给予基金支持，感谢肾移植科的各位医生在病人随访过程中给予的帮助。</p></sec><sec id="s9"><title>文章引用</title><p>董 芳,申黎艳. 肾移植后糖代谢异常患者血糖变化的影响因素Influencing Factors of Blood Glucose Changes in Patients with Abnormal Glucose Metabolism after Kidney Transplantation[J]. 临床医学进展, 2020, 10(06): 997-1003. https://doi.org/10.12677/ACM.2020.106151</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36157-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Dienemann, T., Fujii, N., Li, Y., et al. (2016) Long-Term Patient Survival and Kidney Allograft Survival in Post-Transplant Diabetes Mellitus: A Single-Center Retrospective Study. Transplant International, 29, 1017-1028.  
&lt;br&gt;https://doi.org/10.1111/tri.12807</mixed-citation></ref><ref id="hanspub.36157-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">王新军, 于文. 2012年糖尿病诊疗指南——美国糖尿病协会[J]. 国际内分泌代谢杂志, 2012(3): 211-214.</mixed-citation></ref><ref id="hanspub.36157-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Pham, P.T., Pham, P.M., Pham, S.V., et al. (2011) New Onset Diabetes after Transplantation (NODAT): An Overview. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 4, 175-186. &lt;br&gt;https://doi.org/10.2147/DMSO.S19027</mixed-citation></ref><ref id="hanspub.36157-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Goldmannova, D., Karasek, D., Krystynik, O., et al. (2016) New-Onset Diabetes Mellitus after Renal Transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 160, 195-200.</mixed-citation></ref><ref id="hanspub.36157-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tomkins, M., Tudor, R.M., Cronin, K., et al. (2019) Risk Factors and Long-Term Consequences of New-Onset Diabetes after Renal Transplantation. Irish Journal of Medical Science, 189, 497-503.  
&lt;br&gt;https://doi.org/10.1007/s11845-019-02112-6</mixed-citation></ref><ref id="hanspub.36157-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kwan, J.M., Hajjiri, Z., Metwally, A., et al. (2016) Effect of the Obesity Epidemic on Kidney Transplantation: Obesity Is Independent of Diabetes as a Risk Factor for Adverse Renal Transplant Outcomes. PLoS ONE, 11, e0165712.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0165712</mixed-citation></ref><ref id="hanspub.36157-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J., Xu, L., Wei, X., et al. (2018) Incidence and Risk Factors of Posttransplantation Diabetes Mellitus in Living Donor Kidney Transplantation: A Single-Center Retrospective Study in China. Transplantation Proceedings, 50, 3381-3385. &lt;br&gt;https://doi.org/10.1016/j.transproceed.2018.08.007</mixed-citation></ref><ref id="hanspub.36157-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jenssen, T. and Hartmann, A. (2019) Post-Transplant Diabetes Mellitus in Patients with Solid Organ Transplants. Nature Reviews Endocrinology, 15, 172-188. &lt;br&gt;https://doi.org/10.1038/s41574-018-0137-7</mixed-citation></ref><ref id="hanspub.36157-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gulsoy Kirnap, N., Bozkus, Y. and Haberal, M. (2020) Analysis of Risk Factors for Posttransplant Diabetes Mellitus after Kidney Transplantation: Single-Center Experience. Experimental and Clinical Transplantation, 18, 36-40.  
&lt;br&gt;https://doi.org/10.6002/ect.TOND-TDTD2019.O8</mixed-citation></ref><ref id="hanspub.36157-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Xie, L., Tang, W., Wang, X., et al. (2016) Pretransplantation Risk Factors Associated with New-Onset Diabetes after Living-Donor Kidney Transplantation. Transplantation Proceedings, 48, 3299-3302.  
&lt;br&gt;https://doi.org/10.1016/j.transproceed.2016.10.026</mixed-citation></ref><ref id="hanspub.36157-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Cosis, F.G., Pesawento, T.E., Pelletier, R.P., et al. (2002) Patient Survival after Renal Transplantation III: The Effects of Statins. American Journal of Kidney Diseases, 40, 638-643. &lt;br&gt;https://doi.org/10.1053/ajkd.2002.34927</mixed-citation></ref><ref id="hanspub.36157-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Gomes, V., Ferreira, F., Guerra, J., et al. (2018) New-Onset Diabetes after Kidney Transplantation: Incidence and Associated Factors. World Journal of Diabetes, 9, 132-137. &lt;br&gt;https://doi.org/10.4239/wjd.v9.i7.132</mixed-citation></ref><ref id="hanspub.36157-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Dedinska, I., Palkoci, B., Miklusica, J., et al. (2017) Metabolic Syndrome and New Onset Diabetes after Kidney Transplantation. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews, 11, 211-214.  
&lt;br&gt;https://doi.org/10.1016/j.dsx.2016.06.027</mixed-citation></ref><ref id="hanspub.36157-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Choudhury, P.S., Mukhopadhyay, P., Roychowdhary, A., et al. (2019) Prevalence and Predictors of “New-Onset Diabetes after Transplantation” (NODAT) in Renal Transplant Recipients: An Observational Study. Indian Journal of Endocrinology and Metabolism, 23, 273-277. &lt;br&gt;https://doi.org/10.4103/ijem.IJEM_178_19</mixed-citation></ref><ref id="hanspub.36157-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">De Mattos, A.M., Oiyaei, A.J., Prather, J.C., et al. (2005) Autosomal-Dominant Polycystic Kidney Disease as a Risk Factor for Diabetes Mellitus Following Renal Transplantation. Kidney International, 67, 714-720.  
&lt;br&gt;https://doi.org/10.1111/j.1523-1755.2005.67132.x</mixed-citation></ref><ref id="hanspub.36157-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Pietrzak-Nowacka, M., Safranow, K., Rozanski, J., et al. (2008) Autosomal Dominant Polycystic Kidney Disease Is Not a Risk Factor for Post-Transplant Diabetes Mellitus. Matched-Pair Design Multicenter Study. Archives of Medical Research, 39, 312-319. &lt;br&gt;https://doi.org/10.1016/j.arcmed.2007.10.003</mixed-citation></ref><ref id="hanspub.36157-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Marin, M., Renoult, E., Bondor, C.I., et al. (2005) Factors Influencing the Onset of Diabetes Mellitus after Kidney Transplantation: A Single French Center Experience. Transplantation Proceedings, 37, 1851-1856.  
&lt;br&gt;https://doi.org/10.1016/j.transproceed.2005.03.140</mixed-citation></ref><ref id="hanspub.36157-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">杨进, 方芳, 杨富. 肾移植术后新发糖尿病: 危险因素的回顾性分析[J]. 中国组织工程研究, 2017, 21(20): 3275-3280.</mixed-citation></ref><ref id="hanspub.36157-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Martinez-Castelao, A., Hernandez, M.D., Pascual, J., et al. (2005) Detection and Treatment of Post Kidney Transplant Hyperglycemia: A Spanish Multicenter Cross-Sectional Study. Transplantation Proceedings, 37, 3813-3816.  
&lt;br&gt;https://doi.org/10.1016/j.transproceed.2005.10.035</mixed-citation></ref></ref-list></back></article>